Background {#Sec1}
==========

Dialysis is a successful therapeutic process used for removing metabolic waste from the body fluids of patients with end-stage renal disease (ESRD). There are two primary types of dialysis, namely peritoneal dialysis (PD) and hemodialysis \[[@CR1]\]. More than one million ESRD people worldwide regularly undergo renal dialysis \[[@CR1], [@CR2]\]. However, microbial infection remains one of the most common complications among patients receiving renal dialysis \[[@CR3]\]. According to a retrospective study of 327,993 renal dialysis patients conducted in the USA, chronic dialysis recipients have nearly 10 times the risk of fungal infections compared to the general population \[[@CR4]\]. The cumulative annual incidence of infection-related hospitalization during renal dialysis was 26% for children and 31% for adults in the USA \[[@CR5]\].

In addition to bacterial and viral infections, fungal infections are becoming increasingly frequent among renal dialysis patients, with significant morbidity and mortality rates \[[@CR6]\]. For example, fungal infections account for an estimated 5% of all PD-related peritonitis and have a higher mortality rate than bacterial PD-related peritonitis, with a mortality of 8.6--40.6% \[[@CR4]\]. *Candida* spp. (70%) was the overwhelming microbial pathogen that caused fungal infections in patients receiving renal dialysis, followed by *Cryptococcus* spp. (6%) and *Coccidioides* spp. (4%) \[[@CR4]\]. These data suggest that further attention should be paid to prevent or to timely diagnose fungal infections among ESRD patients during renal dialysis therapy.

The *Cryptococcus* genus, which belongs to the Basidiomycota, is the second most common group of fungal pathogens associated with renal dialysis patients \[[@CR4], [@CR7]--[@CR9]\]. *Cryptococcus neoformans* and *C. gattii* are the main *Cryptococcus* species causing infections in humans. In contrast, *Cryptococcus laurentii*, *Cryptococcus albidus* and *Cryptococcus arboriformis* are generally regarded as saprophytes and have been rarely reported as agents causing human infections \[[@CR10]\]. However, there has been an incremental rise in infections due to these organisms over recent decades \[[@CR11]\]. This increase may reflect enhanced awareness of such infections, improved laboratory detection technology and a rise in the number of at-risk patients. These infections have a similar clinical presentation as those caused by *C. neoformans* or *C. gattii*, but cryptococcal antigen (CrAg) test results are frequently negative and the antifungal susceptibility patterns of these species are characterized by higher MICs \[[@CR11], [@CR12]\].

Despite the remarkable achievement of renal dialysis in prolonging the life of ESRD patients, the use of dialysis is problematic in some respects, such as fungal infection. Individual case reports of cryptococcosis in renal dialysis patients have been reported worldwide since 1980, and particularly since 2010. Currently, our understanding of cryptococcosis during renal dialysis is scarce and fragmented, which makes it challenging for physicians to timely diagnose and treat it among patients undergoing renal dialysis. Hence, we sought to perform a retrospective pooled analysis of the association between cryptococcosis and dialysis patients in our hospital and systematically reviewed the published reports, with a focus on epidemiology and clinical characteristics.

Methods {#Sec2}
=======

Case Collection {#Sec3}
---------------

This study was conducted in Shanghai Changzheng hospital, a top renal dialysis center in Shanghai, China, which receives 85,000 renal dialysis cases annually. The protocol for this study was approved by the Institutional Review Board of Shanghai Changzheng Hospital (approval number 2016SL021). The cases included in the pooled analysis consisted of original cases from our hospital and published reports in electronic databases. The original cases were patients with a discharge diagnosis of "cryptococcosis" or "renal dialysis" who were admitted to our hospital between January 2001 and December 2016 and identified in the inpatient medical record database. We further systematically reviewed cases published in four major electronic literature databases: PubMed, Embase, ISI Web of Science, and Science Direct. The searches were limited to those written in English. The main search terms used were "cryptococcosis" and "dialysis," both as MeSH terms and free text words. A definitive diagnosis of cryptococcosis was defined as the identification of positive findings upon *Cryptococcus* culture, India ink staining, histology, or a CrAg test.

Data Collection and Statistical Analysis {#Sec4}
----------------------------------------

After the cases were identified, the following data were extracted for (1) demographic and epidemiological data, (2) clinical manifestations and laboratory test results, (3) mycological results, and (4) treatment strategies and outcomes. SPSS (version 21, International Business Machines Corporation, Armonk, NY, USA) and Graph Pad Prism (version 5, Graph Pad Software, Inc. La Jolla, CA, USA) were used for statistical analysis. Results are presented as the means ± standard deviations (SDs) for normal data. A *P* value of less than 0.05 was considered statistically significant.

Results {#Sec5}
=======

Case Review and Analysis {#Sec6}
------------------------

A total of 754 articles were identified in the initial screen of the four international databases. Of these articles, 735 were excluded because of duplication and/or an inappropriate content. Nearly all of these pooled cases of cryptococcosis during renal dialysis were single case reports \[[@CR13]--[@CR27]\]. Among these, 16 cases reported in 15 articles with definitive diagnosis of cryptococcosis were analyzed further. In addition, we reported two renal dialysis cases with cryptococcosis who were hospitalized at our hospital. Consequently, 18 cases were pooled for analysis in the current study. The details of these cases are provided in Fig. [1](#Fig1){ref-type="fig"}.Fig. 1Flow diagram of the search and review processes to identify cryptococcosis cases in renal dialysis patients

Demographic and Epidemiologic Characteristics {#Sec7}
---------------------------------------------

Among the 18 pooled cases, 10 cases were reported among PD patients and the remaining eight occurred among hemodialysis patients. The median duration of renal dialysis for PD and hemodialysis cases was 8 months (range 0.25--48 months) and 36 months (24--228 months), respectively. One PD-patient died because of cryptococcosis, and two patients with hemodialysis died because of cryptococcosis during renal dialysis therapy. All of the pooled patients were reported from medical centers in upper-middle to high-income countries (classification based on World Bank data: <http://data.worldbank.org/about/country-and-lending>- groups), with a male: female gender ratio of 13:5. Half of the pooled cases were reported since 2009. Most of the pooled cases were reported in the USA (38.9%, 7/18), followed by Japan (16.7%, 3/18), China (16.7%, 2/18), UK (16.7%, 2/18), Spain (5.6%, 1/18), Korea (5.6%, 1/18), Brazil (5.6%, 1/18), and New Zealand (5.6%, 1/18). The age range containing most patients was 51--60 years (27.8%, 5/18), and most patients were adults (aged ≥ 16 years old; 88.9%, 16/18). Details of the demographic and epidemiologic characteristics of the pooled cases are provided in Table [1](#Tab1){ref-type="table"} and Fig. [2](#Fig2){ref-type="fig"}.Table 1Epidemiological characteristics of cryptococcosis during renal dialysis, 1985--2016CaseDateSex/ageDialysis typeGeographical locationPigeon contactPrevious dialysis duration (months)PrognosisReferences11986M/24PDJacksonville, USAND12Cured\[[@CR18]\]2May 1988F/16PDLittle Rock, USAND0.25Cured\[[@CR20]\]3May 1988F/49PDLittle Rock, USAND0.5Died\[[@CR20]\]4May 1989M/52PDManchester, UKND7Cured\[[@CR19]\]5Nov 1989F/13PDTampa, USAND12Cured\[[@CR16]\]61992F/50PDPorirua, New ZealandND8Cured\[[@CR21]\]7Oct 1993M/48PDNew York, USAND6Cured\[[@CR22]\]8Mar 2014M/57PDNew York, USANeg48Cured\[[@CR14]\]9Jul 2014M/58PDSeoul, KoreaND10Cured\[[@CR15]\]10Apr 2015M/32PDOsaka city, JapanND36Cured\[[@CR13]\]11Aug 1985M/22HemodialysisBristol, UKND24Cured\[[@CR23]\]12Sep 1993M/37HemodialysisPhiladelphia, USAND228Cured\[[@CR17]\]13Aug 2009F/60HemodialysisCuritiba, BrazilND48Died\[[@CR24]\]14Jan 2009M/49HemodialysisMatsuyama, JapanND0.25Died\[[@CR27]\]15Sep 2009M/64HemodialysisOkinawa, JapanPos60Cured\[[@CR26]\]16Jun 2012M/53HemodialysisOviedo, SpainND24Cured\[[@CR25]\]17May 2012M/36HemodialysisShanghai, ChinaNeg24CuredThis study18Aug 2014M/45HemodialysisShanghai, ChinaNeg96CuredThis study*PD* peritoneal dialysis, *M* male, *F* female, *ND* no data Fig. 2Epidemiological profiles of renal dialysis patients with cryptococcosis in the present study, 1985--2016

Clinical Manifestations {#Sec8}
-----------------------

Among the 10 PD cases, most cryptococcal infections occurred in the abdomen ascites (60%, 6/10), followed by two cases involving both the abdomen ascites and cerebrospinal fluid (CSF), one case involving the abdomen ascites and blood, and one case involving the abdomen ascites, blood and CSF. Fever (70.0%, 7/10), cloudy dialysate (70.0%, 7/10), and abdominal pain (50.0%, 5/10) were the most common clinical features. Remarkably, bacterial peritonitis was diagnosed frequently (30.0%, 3/10) in our pooled PD patients. The most common bacterial pathogens in this study were *Aeromonas hydrophila*, *Staphylococcus epidermidis*, and *Streptococcus* group D.

In contrast, the infection sites were variable among the 8 hemodialysis patients, including blood (*n* = 5), cervical lymphocytes (*n* = 1), pleural cavity (*n* = 2), pulmonary capillary embolism (*n* = 1), and skin (*n* = 1). Two patients were each infected at two body sites. Fever (50.0%, 4/8) was the most common clinical feature, followed by headache (25.0%, 2/8), cough (25.0%, 2/8), pleural effusion (25.0%, 2/8), cervical lymphadenopathy (12.5%, 1/8), and erythematous lesions (12.5%, 1/8). Details of the clinical manifestations are shown in Table [2](#Tab2){ref-type="table"} and Fig. [3](#Fig3){ref-type="fig"}.Table 2Clinical characteristics of cryptococcosis during renal dialysisCasesAffected siteMain manifestationPrevious antibioticsReferences1AbdomenAbdominal painCefadyl\[[@CR18]\]2Abdomen + blood + CSFFeverND\[[@CR20]\]3Abdomen + CSFAbdominal pain + feverND\[[@CR20]\]4Abdomen + bloodCloudy dialysate + feverND\[[@CR19]\]5AbdomenAbdominal pain + cloudy dialysate + feverVancomycin\[[@CR16]\]6Abdomencloudy dialysateND\[[@CR21]\]7Abdomen + CSFCloudy dialysate + feverNeg\[[@CR22]\]8AbdomenAbdominal pain + cloudy dialysateVancomycin\[[@CR14]\]9AbdomenAbdominal pain + cloudy dialysate + feverImipenem\[[@CR15]\]10AbdomenCloudy dialysate + feverNeg\[[@CR13]\]11Cervical lymphocyte + bloodcervical lymphadenopathy + feverND\[[@CR23]\]12Pleural cavityCough + feverND\[[@CR17]\]13BloodFeverND\[[@CR24]\]14Pulmonary capillary embolismSevere hypoxia + dyspneaVancomycin\[[@CR27]\]15Pleural cavityCoughND\[[@CR26]\]16Skin + bloodCutaneous ulcerationND\[[@CR25]\]17Blood + CSFHeadacheNDThis study18Blood + CSFHeadache + feverNDThis study*CSF* cerebrospinal fluid, *ND* no data Fig. 3Clinical characteristics and the related cryptococcus species in the pooled renal dialysis patients

Diagnostic Profile {#Sec9}
------------------

Regarding the diagnostic profiles of the 18 pooled cases, 16 were diagnosed using cultures, 12 were diagnosed using CrAg tests, and two cases were diagnosed using India ink staining and histology. All cases (100%, 4/4) caused by non-*C. neoformans*/*C. gattii* were CrAg-negative. Notably, multiple *Cryptococcus* species were observed in the 16 cases diagnosed using cultures, including *C. neoformans* (68.7%, 11/16), *C. laurentti* (12.5%, 2/16), *C. albidus* (12.5%, 2/16), and *C. arboriformis* (6.3%, 1/16). The details are provided in Table [3](#Tab3){ref-type="table"}.Table 3Diagnosis profile of cryptococcosis during renal dialysis*Cryptococcus* speciesSerum CrAgDiagnostic evidenceReferences*C. laurentii*NegCulture\[[@CR16]\]*C. albidus*NegCulture\[[@CR14]\]*C. arboriformis*NegCulture\[[@CR15]\]*C. laurentii*NegCulture\[[@CR13]\]*C. albidus*NDCulture\[[@CR17]\]*Cryptococcus* spp.NDCulture\[[@CR18]\]*C. neoformans*/C. *gattii* complex\>1:12000Culture\[[@CR19]\]*C. neoformans*/*C.gattii* complex1:512Culture\[[@CR20]\]*C. neoformans*/*C. gattii* complexNDCulture\[[@CR20]\]*C. neoformans* var. *neoformans*NDCulture\[[@CR21]\]*C. neoformans*/*C. gattii* complex1:10000Culture\[[@CR22]\]*C. neoformans*/*C. gattii* complexNegHistology\[[@CR23]\]*C. neoformans*/*C. gattii* complexNDCulture\[[@CR24]\]*C. neoformans* var. *neoformans*1:2048Culture + histology\[[@CR25]\]*C. neoformans*/*C. gattii* complex1:320CultureThis study*C. neoformans*/*C. gattii* complex1:5120CultureThis study*C. neoformans*/*C. gattii* complexNegCulture\[[@CR26]\]*Cryptococcus* spp.NDMicroscopic examination\[[@CR27]\]*Cr Ag* cryptococcal antigen, *ND* no data

Treatment and Outcome {#Sec10}
---------------------

The antifungal therapies used to treat the pooled cases were highly variable: amphotericin B (AmB) in combination with 5-fluorocytosine (5-FC) was used in seven cases, followed by AmB alone in six cases, AmB in combination with voriconazole (VCZ) in one case, AmB in combination with fluconazole (FCZ) in one case, VCZ alone in one case, VCZ in combination with 5-FC in one case, and ketoconazole (KCZ) in combination with FCZ in one case. In addition, catheters were removed from all the PD patients (100%, 10/10) after the identification of cryptococcosis, whereas only one hemodialysis patient (12.5%, 1/8) had the catheter removed. The details are provided in Table [4](#Tab4){ref-type="table"}.Table 4Treatment profile of cryptococcosis during renal dialysisCaseRemoval of catheterAntifungal treatmentOutcomeReferences1YesAmB (cumulative dose, 0.3 g)Switching to permanent hemodialysis\[[@CR18]\]2YesAmB (cumulative dose, 2 g)Cured\[[@CR20]\]3YesAmB + 5-FCDied\[[@CR20]\]4YesAmB (cumulative dose, 1.4 g) + 5-FC (cumulative dose, 55 g)Switching to permanent hemodialysis\[[@CR19]\]5YesMCZ × 3 days + AmB (cumulative dose, 0.5 g)Cured\[[@CR16]\]6YesKCZ 400 mg/day × 2 days + FCZ 400 mg/day × 5 daysCured\[[@CR21]\]7YesAmB 0.5 mg/kg/day × 6 weeks +5-FC × 4 weeksSwitching to permanent hemodialysis\[[@CR22]\]8Yes(FCZ 200 mg/day + CPF 50 mg/day) × 5 days + AmB liposomal 400 mg/day × 7 daysSwitching to permanent hemodialysis\[[@CR14]\]9YesFCZ200 mg/day × 6 days + AmB 0.5 mg/kg/day × 4 weeksSwitching to permanent hemodialysis\[[@CR15]\]10YesVCZ 500 mg × 8 daysCured\[[@CR13]\]11NoAmB (cumulative dose, 2.5 g) + 5-FC 50 mg/kg × 6 weeksCured\[[@CR23]\]12NoAmB (cumulative dose, 1.9 g)Cured\[[@CR17]\]13YesAmB 0.5 mg/kg/day × 6 weeksDied\[[@CR24]\]14NDNDDied\[[@CR27]\]15No(AmB + 5-FC) × 9 days + FCZ × 24 weeksCured\[[@CR26]\]16NoVCZ 400 mg/d × 10 days + AmB 100 mg/day × 4 days + Cured\[[@CR25]\]17No(VCZ 0.4 g/day + 5-FC 4 g/day) × 2 weeksCuredThis study18No(AmB 30 mg/days + 5-FC 4.5 g/day) × 4 weeksCuredThis study*AmB* Amphotericin B, *VCZ* voriconazole, *FCZ* fluconazole, *KCZ* ketoconazole, *MCZ* miconazole, *5-FC* 5-fluorocytosine, *CPF* caspofungin, *ND* no data

Discussion {#Sec11}
==========

Previous studies have shown that cryptococcosis can occur in HIV-negative patients \[[@CR28], [@CR29]\]. However, a detailed profile of cryptococcosis occurring after renal dialysis is difficult to determine. Recent studies suggested that non-*C*. *neoformans*/*C*. *gattii* species, which have higher MICs of current antifungal drugs, accounted for a large proportion of cryptococcal infections among renal dialysis patients \[[@CR13]--[@CR17]\]. Hence, cryptococcosis in renal dialysis patients should be further studied due to our poor understanding of this infection.

The current study showed that male adult patients were dominant among renal dialysis recipients with cryptococcosis, which is consistent with previous studies \[[@CR30], [@CR31]\]. A considerable number of pooled cases (5/18) occurred in the past 5 years, which is likely to be related to the increasing number of renal dialysis patients worldwide \[[@CR3]\]. Most of the current cases were collected from medical centers in major cities worldwide, including New York in the USA, Osaka in Japan, and Shanghai in China \[[@CR13], [@CR14], [@CR22]\]. Thus, the availability of modern diagnostic tools might be relevant to the relatively high level of diagnosed cryptococcal infections in these cities. Although HIV infection is the most common underlying risk factor for cryptococcal infection \[[@CR11], [@CR12]\], none of the renal dialysis recipients with cryptococcosis were reported to be HIV-positive in the current study. However, we cannot neglect the risk of cryptococcosis among renal dialysis recipients who also have HIV infections.

The current survey found several different characteristics between PD and hemodialysis patients with cryptococcosis. For example, the duration of exposure to renal dialysis is directly related to the risk of septicemia \[[@CR32]\], because a longer duration of renal dialysis may have a cumulative detrimental effect on immunity. In the current study, the median duration of hemodialysis was nearly threefold longer than that of PD cases. However, there were nearly twice as many reported cases of cryptococcosis in PD patients than hemodialysis patients, which indicated that peritoneal dialysis patients might have a higher risk for cryptococcosis compared with hemodialysis patients. Remarkably, cryptococcal infections tend to be localized in the abdomen of PD patients (60.0%, 6/10). In contrast, the sites of cryptococcal infection vary among hemodialysis patients, including skin, lungs, and blood. Moreover, the current data suggest that several PD patients (40.0%, 4/10) had previously been treated for bacterial peritonitis. This finding is consistent with a study \[[@CR33]\] encompassing 66 centers in Australia over a 4-year period, which indicated that previously treated bacterial peritonitis is a major risk factor for fungal peritonitis.

*Cryptococcus neoformans* and *C. gattii* species are responsible for almost all human cryptococcal infections \[[@CR7]\]. Other cryptococcal species were traditionally considered to be nonpathogenic \[[@CR11], [@CR12]\]. However, cases of cryptococcosis caused by non-*C*. *neoformans*/*C*. *gattii* have increased significantly since the 1970s, including in renal dialysis patients. The results of the current study also revealed that non-*neoformans*/*gattii* cryptococcal species account for a considerable proportion (approximately 27.8%, 5/18) of the cryptococcal species among renal dialysis patients \[[@CR13]--[@CR17]\], particularly *C. laurentii* or *C. albidus*. This observation is consistent with a recent global review of 44 previously published cases \[[@CR11]\]. Notably, the current results suggest that CrAg tests are ineffective for the diagnosis of cryptococcosis caused by non-*C*. *neoformans*/*C*. *gattii* species, although this test is considered as a powerful tool for the diagnosis of cryptococcal infections caused by *C*. *neoformans* or *C*. *gattii* species \[[@CR34]--[@CR36]\]. The discrepancy in the sensitivity of CrAg test might be related to the significant phylogenetic divergence between non-*C*. *neoformans*/*C*. *gattii* species and *C*. *neoformans*/*C*. *gattii* species complex \[[@CR8], [@CR9]\]. Indeed, recent phylogenetic studies have reclassified *C. laurentii* to *Papiliotrema laurentii*, *C. albidus* to *Naganishia albida* and *C. arboriformis* to *Cutaneotrichosporon arboriformis* \[[@CR8], [@CR9]\]. Another potential cause of the negative CrAg test for infections caused by *C. laurentii* and *C. albidus* might be related to a lower organism burden in cryptococcemia caused by these non-*C*. *neoformans*/*C*. *gattii* species \[[@CR11]\]. Thus, a negative CrAg test result cannot rule out cryptococcal infections caused by non-*C*. *neoformans*/*C*. *gattii* species \[[@CR37]\].

Regarding the treatment of cryptococcosis among dialysis patients in this study, the catheter was removed from most PD patients (91%) after the identification of a cryptococcal infection. This is consistent with a recent retrospective review indicating that catheters should be removed immediately and certainly within 24 h after the identification of fungi in PD patients with fungal peritonitis \[[@CR38]\]. In contrast, only one hemodialysis patient had the catheter removed. Moreover, it has been shown that the risks of recurrent fungal peritonitis and death were lowest when the catheter removal is combined with antifungal therapy compared with either intervention alone \[[@CR33]\]. In addition, multiple antifungal agents were used to treat cryptococcosis patients with renal dialysis in the current study, including AmB, FCZ, VCZ, KCZ, and flucytosine. Among these, AmB is the most frequently used antifungal drug, which is consistent with the 2010 guidelines for the treatment of cryptococcosis \[[@CR39]\]. Treatment with AmB and FCZ is the previous recommendations for cryptococcal infections caused by non-*C*. *neoformans*/*C*. *gattii* species, including *C. albidus*, *C. laurentii*, *C. uniguttulatus* and *C. curvatus*, according to the results of an in vitro susceptibility study \[[@CR12]\]. In addition, recent susceptibility testing of *C. arboriformis* revealed that the isolate was susceptible to AmB and FCZ, with intermediate sensitivity to flucytosine \[[@CR15]\]. Further studies on renal dialysis recipients with cryptococcosis are needed to develop more effective and consistent treatment strategies.

In conclusion, cryptococcosis is a neglected complication among renal dialysis recipients and has shown an increasing tendency in recent years. Multiple species, such as *C. albidus*, *C. laurentii* and *C. arboriformis*, were observed with nonspecific clinical manifestations. Physicians should consider the possibility of cryptococcosis among renal dialysis recipients, even for those with a negative CrAg test result. The timely removal of the catheter was shown to be crucial for the successful recovery of PD patients with cryptococcosis. Optimizing antifungal treatment strategy in renal dialysis recipients with cryptococcal infections is needed.
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